Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.55 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.55 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.55 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.55 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.55 |
| ▸ | CYP2C18 | P33260 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.55 |
| ▸ | CYP4F8 | P98187 | 1/20 | 0.55 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15641765 | 0.87 | CYP1A1 (0.50) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL8987283 | 0.85 | CYP1A1 (0.74) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL2407878 | 0.85 | CYP1A1 (0.74) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL27404494 | 0.83 | SLC6A2 (0.51) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL26498639 | 0.81 | CYP1A1 (0.83) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL26498734 | 0.81 | CYP1A1 (0.83) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL26498789 | 0.81 | CYP1A1 (0.83) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL1710738 | 0.79 | CYP1A1 (0.50) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL45718 | 0.78 | ALDH1A1 (0.60) | CYP1A2CYP3A4SLC6A2SLC6A4NPC1 | |
| SCHEMBL1562747 | 0.78 | ALDH1A1 (0.60) | CYP1A2CYP3A4SLC6A2SLC6A4NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4618755-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | Larkspur Biosciences, Inc. (US) | 2025-09-24 | — | — | EP | disclosed |
| US-12018037-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-06-25 | — | — | US | disclosed |
| US-12018037-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-06-25 | — | — | US | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| WO-2024107746-A1 | INHIBITORS AND DEGRADERS OF PIP4K PROTEIN | LARKSPUR BIOSCIENCES (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3416956-B1 | METHYLAMINE DERIVATIVES AS LYSYL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL (GB) | 2024-04-10 | — | — | EP | disclosed |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2023-03-21 | — | — | US | disclosed |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2022-11-24 | — | — | US | disclosed |
| CN-109311839-B | Methylamine derivatives as lysyl oxidase inhibitors for the treatment of cancer | 癌症研究协会皇家癌症医院 | 2021-11-02 | — | — | CN | disclosed |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2021-05-04 | — | — | US | disclosed |
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2019-05-23 | — | — | US | disclosed |
| EP-3416956-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | The Institute of Cancer Research : The Royal Cancer Hospital (GB) | 2018-12-26 | — | — | EP | disclosed |
| WO-2017141049-A1 | METHYLAMINE DERIVATIVES AS LYSYSL OXIDASE INHIBITORS FOR THE TREATMENT OF CANCER | THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (GB) | 2017-08-24 | — | — | WO | disclosed |
| US-5350846-A | Antibiotics | MERCK & CO., INC. (US) | 1994-09-27 | — | — | US | disclosed |
| US-5208329-A | Antibacterial agents | MERCK & CO., INC. (US) | 1993-05-04 | — | — | US | disclosed |
| US-5182385-A | Chemical intermediates for bactericides | MERCK & CO., INC. (US) | 1993-01-26 | — | — | US | disclosed |
| EP-0467434-A1 | 2-Biphenyl-carbapenem antibacterial agents | MERCK & CO. INC. (US) | 1992-01-22 | — | — | EP | disclosed |
| EP-0464900-A2 | 2-Biphenyl-carbapenems | MERCK & CO. INC. (US) | 1992-01-08 | — | — | EP | disclosed |
| US-5025006-A | Carbapenicillin antibiotics | MERCK & CO., INC. (US) | 1991-06-18 | — | — | US | disclosed |
| US-5011832-A | 2-biphenyl-carbapenem antibacterial agents | MERCK & CO., INC. (US) | 1991-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190152966-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | CYP1A1 1061/4885CYP1A2 1416/4885CYP2E1 1271/4885 |
| US-20220372028-A1 | Methylamine Derivatives as Lysysl Oxidase Inhibitors for the Treatment of Cancer | LOXL1, LOXL3, LOXL2 | CYP1A1 1061/4885CYP1A2 1416/4885CYP2E1 1271/4885 |
| US-12018037-B2 | Organometallic compound, organic light-emitting device including the organometallic compound, and diagnostic composition including the organometallic compound | ORC3, LEF1, OCIAD1 | CYP1A1 188/4885CYP1A2 779/4885CYP2E1 283/4885 |
| US-10995088-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | CYP1A1 1061/4885CYP1A2 1416/4885CYP2E1 1271/4885 |
| US-11608330-B2 | Methylamine derivatives as lysysl oxidase inhibitors for the treatment of cancer | LOXL1, LOXL3, LOXL2 | CYP1A1 1061/4885CYP1A2 1416/4885CYP2E1 1271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.